Table 1 Asthma control and FeNO

Covar RA, JPediatr 2003

5– 12

92 with mild to moderate asthma

. degree of bronchial hyperresponsiveness

Yes

. bronchodilator reversibility

. allergen skin prick tests

. serum IgE

. eosinophil count

. nocturnal symptoms, β- agonist use at least once weekly.

Smith AD, J Allergy ClinImmunol 2009

12– 75

73 with chronic asthma in treatment with ICS

. asthma control (changes in symptoms, bronchodilator use, diurnal peak flows, spirometry)

No

Fritsch M, Pediatr Pulmonol 2006

6 –18

47 with mild to moderate persistent asthma

. dose of ICS (p < 0.002)

Yes

. b-agonist use 2 weeks prior to a visit (p<0.05)

. asthma symptoms (p < 0.0001)

. bronchial hyperresponsiveness (p = 0.02)

Waibel V, Pediatr Pulmonol 2012

12 (mean age)

107 with a diagnosis of asthma

. C-ACT

No

Cabral ALB, AnnalsAllergy Asthma Immunol 2009

7– 14

32 with moderate-to-severe asthma

. risk for exacerbations

No

Green RJ, Chest 2013

4– 11

71 with atopic asthma

. spirometry

No

. ACT